Navigation Links
Pharmasset to Webcast an Investor Event from the AASLD Meeting
Date:11/1/2009

PRINCETON, N.J., Nov. 1 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS) today announced that it will webcast an investor event from the American Association for the Study of Liver Diseases (AASLD) on Monday, November 2, 2009 starting at 7:00pm ET. During this webcast, management will review Pharmasset's progress on the programs that are the subject of presentations at AASLD.

To access a simultaneous webcast of this event via the internet, log on to the "Events & Presentations" section of the Investor Center on Pharmasset's website at http://investor.pharmasset.com/events.cfm . Please connect to the website at least ten minutes prior to the start of the presentation to ensure adequate time for a reliable connection and any software download that may be necessary for the webcast. The following abstracts are available on the AASLD website (AASLD.org).

PSI-7851

Late Breaker Abstract 17

"Antiviral Activity, Pharmacokinetics, Safety, and Tolerability of PSI-7851, a Novel Nucleotide Polymerase Inhibitor for HCV, Following Single and 3 Day Multiple Ascending Oral Doses in Healthy Volunteers and Patients with Chronic HCV Infection" will be presented in a late breaker poster session on Monday November 2nd at 8am ET. Authors of the study are M. Rodriguez-Torres; E. Lawitz; S. Flach; J. M. Denning; E. Albanis; W. Symonds; M. M. Berrey.

RG7128/INFORM-1

Abstract 1585

"Combination Therapy with Nucleoside Polymerase R7128 and Protease R7227/ITMN-191 Inhibitors in Genotype 1 HCV Infected Patients: Interim Resistance Analysis of INFORM-1 Cohorts" will be presented in a poster session on Tuesday November 3rd at 8am ET. Authors of the study are A-D S. Le Pogam; M. Chhabra; S. Ali; J. Yan; M.J. Ilnicka; H. Kang; J.M. Wong; A. Kosaka; A. Ewing; A. Seshaadri; A. De La Rosa; W.Z. Bradford; K.Klumpp; N. Shulman; P.F. Smith; N. Cammack; I. Najera.

Abstract 193

"Combination Therapy With A Nucleoside Polymerase (R7128) And Protease (R7227/ITMN-191) Inhibitors In HCV: Safety, Pharmacokinetics, And Virologic Results From INFORM-1." will be presented at the Presidential Plenary session on Tuesday November 3rd at 8am ET. Authors of the study are E.J. Gane; S.K. Roberts; C.A. Stedman; P.W. Angus; B. Ritchie; R. Elston; D. Ipe; P.N. Morcos; I. Najera; T. Chu; M.M. Berrey; W.Z. Bradford; M. Laughlin; N. Shulman; P.F. Smith.

Abstract 1594

"Pharmacokinetics/Pharmacodynamics (PK/PD) of Combination R7227 and R7128 Therapy From INFORM-1 Demonstrates Similar Early HCV Viral Dynamics When R7227 is Combined With Either PEG-IFN/Ribavirin (SOC) or R7128" will be presented in a poster session on Tuesday November 3rd at 8am ET. Authors of the study are P.N. Morcos; R. Kulkarni; D. Ipe; S. Jumbe; J. Tran; W.Z. Bradford; W. Symonds; W.Z. Bradford; E.J. Gane; S.K. Roberts; N. Shulman; P.F. Smith.

PSI-938

Abstract 1605

"Novel 2 -F-2 -C-Methylpurine Nucleotide Analogs Are Active Inhibitors of HCV Replication And Lack Cross-Resistance with Other Nucleos(t)ide Analogs" will be presented in a poster session on Tuesday November 3rd at 8am ET. Authors of the study are A.M. Lam; C.L. Espiritu; H. Micolochick Steuer; E. Murakami; C. Niu; M. Keilman; D.N. Frick; J.A. Heck; M.J. Sofia; D. Nagarathnam; W. Chang; P.G. Reddy; B.S. Ross; B. Chun; P. Wang; H. Zhang; S. Rachakonda; D. Bao; M.J. Otto; P.A. Furman.

About Pharmasset

Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing, and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis C virus (HCV) and, secondarily, on the development of Racivir(TM) for the treatment of human immunodeficiency virus (HIV). Our research and development efforts focus on nucleoside/tide analogs, a class of compounds which act as alternative substrates for the viral polymerase thus inhibiting viral replication. We currently have three clinical-stage product candidates. RG7128, a nucleoside analog for chronic HCV infections, is in a Phase 2b clinical trial in combination with Pegasys(R) plus Copegus(R) and is also in INFORM studies, the first series of studies designed to assess the potential of combinations of small molecules without Pegasys(R) and Copegus(R) to treat chronic HCV. These clinical studies are being conducted through a strategic collaboration with Roche. Our other clinical stage candidates are PSI-7851, an unpartnered, next generation HCV nucleotide analog which has completed initial Phase 1 clinical studies, and Racivir, for the treatment of HIV, which has completed a Phase 2 clinical trial. We have also recently announced the nomination of two purine nucleotide analogs, PSI-938 and PSI-879, for preclinical development.

Pegasys(R) and Copegus(R) are registered trademarks of Roche.

Forward-Looking Statements

Pharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding our business that are not historical facts are "forward-looking statements" that involve risks and uncertainties, including, without limitation, the risk that adverse events could cause the cessation or delay of any of the ongoing or planned clinical trials and/or our development of our product candidates, the risk that the results of previously conducted studies involving our product candidates will not be repeated or observed in ongoing or future studies involving our product candidates, the risk that our collaboration with Roche will not continue or will not be successful and the risk that any one or more of our product candidates will not be successfully developed and commercialized. For a discussion of these risks and uncertainties, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section of our Annual Report on Form 10-K for the fiscal year ended September 30, 2008 and our Quarterly Report on Form 10-Q for the period ended June 30, 2009 filed with the Securities and Exchange Commission entitled "Risk Factors" and discussions of potential risks and uncertainties in our subsequent filings with the Securities and Exchange Commission.

www.pharmasset.com

    Contact
    Richard E. T. Smith, Ph.D.
    VP, Investor Relations and Corporate Communications
    richard.smith@pharmasset.com
    Office: +1 (609) 613-4181

SOURCE Pharmasset, Inc.


'/>"/>
SOURCE Pharmasset, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Pharmasset and Roche to Present R7128 Data at the 14th International Symposium on Hepatitis C Virus and Related Viruses
2. Pharmasset to Present at the UBS Global Life Sciences Conference on Monday, September 24th
3. Pharmasset Accesses up to $30 Million of Working Capital
4. Pharmasset to Present at Three Investor Conferences in November 2007
5. Pharmasset Appoints Michael Rogers as Chief Development Officer
6. Pharmasset Reports Fiscal Year End 2007 Financial Results
7. Pharmasset to Present at the BIO CEO & Investor Conference 2008 on Monday, February 11th
8. Pharmasset to Present at Susquehannas Second Annual SIGnificant Investment Options in Healthcare Conference on Wednesday, March 5th
9. Pharmasset to Present at Cowen & Companys Health Care Conference on Tuesday, March 18th
10. Pharmasset Appoints Herbert J. Conrad as a Director
11. Pharmasset Receives $10 Million of Working Capital
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... ... May 25, 2016 , ... Biohaven Pharmaceutical ... (FDA) has granted the company’s orphan drug designation request covering BHV-4157 for the ... granted by the FDA. , Spinocerebellar ataxia is a rare, debilitating neurodegenerative ...
(Date:5/24/2016)... TEL AVIV, Israel , May 24, 2016   ... on providing physicians with artificial intelligence, real-time decision support tools ... selected to present at the 2016 Israeli Advanced Technology Industries ... part of Israel,s 15th National Life ... to 26th at the David Intercontinental Hotel in ...
(Date:5/24/2016)... ... May 24, 2016 , ... Media Cybernetics, global image ... Cybernetics corporate branding reflects a results-driven revitalization for a company with a renewed ... components include a crisp, refreshed logo and a new web presence. , “I ...
(Date:5/23/2016)... ... May 23, 2016 , ... PrecisionAg® ... Farming in 2017 and Beyond. The paper outlines the key trends that are ... industry. , “We’ve witnessed a lot of highs and lows as the precision ...
Breaking Biology Technology:
(Date:3/14/2016)... , Allemagne, March 14, 2016 ... ) - --> - Renvoi : image ... --> --> ... biométriques, fournit de nouveaux lecteurs d,empreintes digitales pour ... de DERMALOG sera utilisé pour produire des cartes ...
(Date:3/10/2016)... India , March 10, 2016 ... a new market research report "Identity and Access Management ... & Audit, Compliance, and Governance), by Organization Size, by ... to 2020", published by MarketsandMarkets, The market is estimated ... USD 12.78 Billion by 2020, at a Compound Annual ...
(Date:3/9/2016)... , March 9, 2016 ... government identified that more than 23,000 public service employees ... had been receiving their salary unlawfully.    --> ... country,s government identified that more than 23,000 public service ... or had been receiving their salary unlawfully.    ...
Breaking Biology News(10 mins):